Relay Therapeutics, Inc. (RLAY): R&D Expense
$261.38M
Year ended 2025-12-31
$270.72M
Trailing 12 months to 2026-06-30
+2.0%
3-year compound annual growth
+21.2%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $261.38M | -18.1% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $319.09M | -3.3% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $330.02M | +34.0% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $246.35M | +42.7% | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | $172.65M | +72.9% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $99.86M | +42.0% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $70.31M | n/a | 2022-02-24, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $261.38M | -18.1% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $17.73M | +42.2% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $1.23M | +4.2% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $18.67M | -37.4% |
| Alector, Inc. (ALEC) | 2025-12-31 | $123.06M | -33.8% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $109.44M | -15.9% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $114.15M | +6.3% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $1.87M | -52.4% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $86.40M | +30.9% |
Compare RLAY, LCTX, PTHS, LENZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗